

INTERNATIONAL ENCYCLOPEDIA OF PHARMACOLOGY AND THERAPEUTICS

Sponsored by the International Union of Pharmacology



Section 33 Volume I

Pharmacology of the Cerebral
Circulation

INTERNATIONAL ENCYCLOPEDIA OF
PHARMACOLOGY AND THERAPEUTICS

Pharmacology of the Cerebral Circulation

VOLUME I

CONTRIBUTORS

E. BETZ
L. BOZZAO
L. CAMPAN
A. CARPI
C. CARTONI

P. DEL BASSO
A. D. ERICSSON
J. D. FENSTERMACHER
C. FIESCHI
A. P. FRIEDMAN

V. G. GIARDINI
G. LAZORTHES
J. S. MEYER
D. P. RALL



PERGAMON PRESS

OXFORD

NEW YORK • TORONTO

• SYDNEY

BRAUNSCHWEIG

Pergamon Press Ltd., Headington Hill Hall, Oxford
Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford,
New York 10523
Pergamon of Canada Ltd., 207 Queen's Quay West, Toronto 1
Pergamon Press (Aust.) Pty. Ltd., 19a Boundary Street,
Rushcutters Bay, N.S.W. 2011, Australia
Vieweg & Sohn GmbH, Burgplatz 1, Braunschweig

Copyright © 1972 Pergamon Press Ltd.

All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of Pergamon Press Ltd.

First edition 1972

Library of Congress Catalog Card No.70-182263

*Printed in Great Britain by
Cox & Wyman Ltd., London, Reading and Fakenham*

08 016209 6

INTERNATIONAL ENCYCLOPEDIA OF PHARMACOLOGY AND THERAPEUTICS

Sponsored by the International Union of Pharmacology (IUPHAR)

(Chairman: B. UVNÄS, Stockholm)

Executive Editor: G. PETERS, Lausanne

Section 33

PHARMACOLOGY OF THE CEREBRAL CIRCULATION

Section Editor

AMILCARE CARPI

Istituto Superiore di Sanità, Rome

VOLUME I

EDITORIAL BOARD

D. BOVET, *Rome*

G. PETERS, *Lausanne*

A. S. V. BURGEN, *Cambridge*

C. RADOUCO-THOMAS, *Quebec*

J. CHEYMOL, *Paris*

H. RAŠKOVA, *Prague*

G. B. KOELLE *Philadelphia*

V. V. ZAKUSOV, *Moscow*

M. J. MICHELSON, *Leningrad*

LIST OF CONTRIBUTORS

- EBERHARD BETZ, Institute of Physiology II, University of Tübingen, West Germany.
LUIGI BOZZAO, Neurological Clinic, University of Rome, Italy.
LOUIS CAMPAN, Neurosurgical Clinic, University Hospital Center, Toulouse, France.
AMILCARE CARPI, Department of Therapeutical Chemistry, Istituto Superiore di Sanità, Rome, Italy.
CARLA CARTONI, Department of Therapeutical Chemistry, Istituto Superiore di Sanità, Rome, Italy.
PAOLA DEL BASSO, Department of Therapeutical Chemistry, Istituto Superiore di Sanità, Rome, Italy.
ARTHUR D. ERICSSON, Department of Neurology, Baylor College of Medicine, Texas Medical Center, Houston, Texas, U.S.A.
JOSEPH D. FENSTERMACHER, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, U.S.A.
CESARE FIESCHI, Neurological Clinic, University of Siena, Italy.
ARNOLD P. FRIEDMAN, Headache Unit, Montefiore Hospital, Bronx, New York, U.S.A.
VALERIO GIARDINI, Department of Therapeutical Chemistry, Istituto Superiore di Sanità, Rome, Italy.
GUY LAZORTHES, Neurosurgical Clinic, University Hospital Center, Toulouse, France.
JOHN S. MEYER, Department of Neurology, Baylor College of Medicine, Texas Medical Center, Houston, Texas, U.S.A.
DAVID P. RALL, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, U.S.A.

ABBREVIATIONS USED IN THIS BOOK

A-V	: arterio-venous difference
BBB	: blood-brain barrier
CBF	: cerebral blood flow
CMR	: cerebral metabolic rate
CNS	: central nervous system
CSF	: cerebrospinal fluid
CV	: cerebrovascular
CVR	: cerebral vascular resistance
MABP	: mean arterial blood pressure
ECF	: extracellular fluid
ECS	: extracellular space
EEG	: electroencephalogram
PCO ₂	: partial pressure of CO ₂
PO ₂	: partial pressure of O ₂
rCBF	: regional cerebral blood flow
rCMR	: regional cerebral metabolic rate

PREFACE

IN THE course of the last 8 years numerous technological advances have led to impressive developments in brain-circulation studies. New functional aspects of brain circulation, new physiopathological processes and new therapeutical tendencies and trends have all been expounded. It is somewhat surprising, therefore, to note that brain-circulation pharmacology has fallen behind the other branches of cerebrovascular investigation, thereby indicating that pharmacologists would appear to be rather unconcerned about brain-circulation problems.

This book wishes to demonstrate that this attitude is not justified, and that pharmacological studies performed on experimental animals (which represent the starting point of any well-grounded pharmaco-therapeutical study) have a right to full citizenship in the field of cerebral circulation too. Thus, in recent times, new pharmaco-therapeutical trends have been suggested as the result of clinical observations of the "steal" and "counter-steal" phenomena; in fact, it is not by mere chance alone that these phenomena reflect a principle set forth some time ago by experimental pharmacologists, namely the interrelationships between cerebrovascular reactivity and the functional status of brain circulation.

The reason why experimental pharmacology was not able to, or did not, keep up with the rate of progress achieved by studies on other aspects of brain circulation may be explained in many ways. The part played by technical considerations has been dealt with in this book, but other non-technical factors (for example, the high cost of the experimental research in this field and the limited possibility of rapidly obtaining highly profitable results) have also played their indisputable roles. Therefore, even in the brain-circulation field, we have been faced with the very general and crucial problem of the heavy, and sometimes critical, influence exerted by non-technical motivations in the progress of basic research.

Some aspects of this book will appear rather unusual for a text dealing with pharmacology. Only a certain number of chapters are devoted strictly to the mode and mechanism of the cerebrovascular action of different drugs. A significant part of the book does, however, deal with the physiological, physiopathological and clinico-therapeutical aspects of brain circulation. This part intends to point out some of the gaps still existing in the field of brain-circula-

tion pharmacology. Thus, the chapter dealing with blood-brain exchanges introduces a subject which should be more carefully considered in order to remove future work on brain circulation from the sphere of pure theoretical considerations. The chapters on the physiopathological and clinico-therapeutical aspects of brain circulation are intended to inform the pharmacologist on the possible mechanisms by which well-known drugs, and new drugs, exert, or may exert, their therapeutical effects on brain disturbances of vascular origin.

It has been said, and written, that a book may be useful also as a result of the gaps contained and the unwritten chapters. This is certainly true if the existence and origin of these gaps are discussed and a possible way to write the missing chapters is indicated. This has been the principal aim of this book, which comes about as the result of frank, but also critical, co-operation between the authors. Any success that this book may achieve, therefore, will reflect credit equally on the authors and editor.

AMILCARE CARPI

CONTENTS

LIST OF CONTRIBUTORS	vii
ABBREVIATIONS USED IN THIS BOOK	viii
PREFACE	ix
CHAPTER 1. THE PHYSIOLOGY OF CEREBRAL CIRCULATION	1
<i>C. Fieschi and L. Bozzao</i>	
Normal values and methodology—Cerebral blood flow under different physiological conditions—Neurogenic control of cerebral circulation—Chemical control of CBF—Cerebral blood flow and perfusion pressure—Conclusions. ECF-pH the main factor controlling CBF?—References	
CHAPTER 2. PHYSIOLOGY AND PHARMACOLOGY OF CEREBROSPINAL FLUID	35
<i>J. D. Fenstermacher and D. P. Rall</i>	
Morphology—Cerebrospinal fluid composition—Transport at the various boundaries—Blood-brain-CSF exchange—CSF production and flow—Cerebrospinal fluid pH—Conclusions—References	
CHAPTER 3. THE CLASSIFICATION OF DRUGS ACTING ON CEREBRAL CIRCULATION	81
<i>A. Carpi</i>	
References	
CHAPTER 4. DRUGS RELATED TO CHEMICAL MEDIATORS	87
<i>A. Carpi</i>	
The adrenaline and noradrenaline group—The acetylcholine group—The histamine group—The 5-hydroxytryptamine group—The polypeptide group—Other possible mediators—References (see Chapter 5)	
CHAPTER 5. DRUGS ACTING ON MUSCULAR RECEPTORS	125
<i>A. Carpi and V. Giardini</i>	
The xanthines—Nicotinic acid and its derivatives—Nitrites—Papaverine—Cyclandelate—Dipyridamole—Phthalazine derivatives—References to Chapters 4 and 5	
CHAPTER 6. CENTRAL NERVOUS SYSTEM DEPRESSANTS	149
<i>E. Betz</i>	
Methodology and pharmacodynamics—CBF in conscious and anesthetized subjects—Anesthetics and the interaction between brain functional activity and circulation—Cerebrovascular effects of anesthetics and central depressants—	

	Oxygen uptake and blood flow of the brain in anesthesia— CBF during and after the induction of anesthesia—Effect of anesthetics on the cerebrovascular reactivity—Mechanism of action of anesthetics on CBF—Conclusions—References	
CHAPTER 7.	CENTRAL NERVOUS SYSTEM STIMULANTS	181
	<i>A. Carpi and C. Cartoni</i>	
	Pharmacological premises—Hemodynamic aspects of the cerebrovascular action of analeptics—Functional and bio- chemical concomitants of the cerebrovascular action of analeptics—Influence of vascular reaction on seizure activity—Cerebrovascular effects of different analeptics— Pharmacological approach to the problem of the inter- relation between cerebral functional activity and circulation —References	
CHAPTER 8.	MISCELLANEOUS AGENTS ACTING ON CEREBRAL BLOOD FLOW	203
	<i>A. Carpi and P. del Basso</i>	
	Hormones—Drugs acting on carbon dioxide transport and on acid-base equilibrium—Osmotic agents and plasma expanders—Radiopaque compounds—Miscellaneous drugs acting on the cardiovascular system—References	
CHAPTER 9.	TREATMENT OF VASCULAR HEADACHE	225
	<i>A. P. Friedman</i>	
	Classification—History—Pathogenesis—Treatment of mi- graine—Treatment of nonmigrainous vascular headaches— Conclusions—References	
CHAPTER 10.	CEREBRAL CIRCULATION AND METABOLISM IN NEUROLOGICAL DISORDERS	253
	<i>J. S. Meyer and A. D. Ericsson</i>	
	Coma—Cerebrovascular disease—Conclusions—References	
CHAPTER 11.	DRUGS USED FOR CLINICAL DISORDERS OF CEREBRAL EDEMA AND CEREBRAL COLLAPSE	297
	<i>G. Lazorthes and L. Campan</i>	
	Cerebral edema—Cerebral collapse—References	
CHAPTER 12.	CONCLUSIONS	329
	<i>A. Carpi</i>	
	Segmental reactions of the cerebrovascular tree—Cerebro- vascular reactivity—Experimental and clinical pharma- cology. New approaches—Addendum—References	
AUTHOR INDEX		343
SUBJECT INDEX		355

CHAPTER 1

THE PHYSIOLOGY OF CEREBRAL CIRCULATION

C. Fieschi and L. Bozzao

University of Siena and University of Rome, Italy

NORMAL VALUES AND METHODOLOGY

The cerebral blood flow in healthy adult subjects is about 50 ml. of blood per 100 g tissue per minute. This value, related to the average brain weight, corresponds to a flow of about 750 ml./min for the whole brain. Thus, although the brain weight is only 2–3 per cent of the total body mass, it takes about 20 per cent of the resting cardiac output. Such high perfusion is related to an equally high metabolic rate. In fact, the oxygen metabolic requirement of the brain is about 3 ml./100 g/min, or 45 ml./min for the entire organ, which is 25 per cent of the total O₂ consumption of man at rest.

The metabolic rate and hence the flow are not uniform throughout the brain, although similar in the two hemispheres (Shinohara *et al.*, 1969). CMR for O₂ and CBF are higher in the densely cellular gray matter than in the white matter as shown by the autoradiographic technique with ¹⁴C antipyrine which measures blood flow in discrete areas of the brain (Landau *et al.*, 1955; Reivich *et al.*, 1969). Autoradiography has shown that the brain is composed of a large number of structures with different blood-flow rates (Table 1). Measurements of blood flow in the cerebral cortex, the caudate nucleus and the subcortical

TABLE 1. LOCAL CBF IN THE CONSCIOUS CAT

Structure	Local CBF (ml/g/min) mean \pm s.e.
Sensory-motor cortex	1.38 \pm 0.12
Caudate nucleus	1.10 \pm 0.08
Thalamus	1.03 \pm 0.05
Cerebellum	0.79 \pm 0.05
White matter	0.23 \pm 0.02

From Landau *et al.* (1955), by courtesy of the American Neurological Association.

white matter by clearance methods (Ingvar and Lassen, 1962; Fieschi *et al.*, 1964, 1965) have confirmed the autoradiographic data.

In spite of the different values of blood flow in different regions of the brain there is a clear-cut bimodal distribution of blood-flow rates in the brain (Fig. 1); in this distribution, the modes correspond to the average blood flow to the gray and white structures of the brain. The existence of two distinct patterns of flow in brain, high values for the gray matter and low values for the white matter, has been used for calculation of the blood flow in different regions of the human brain from the extracranially registered clearance curves of a radioactive inert gas (regional cerebral blood flow). This technique, first described by Lassen *et al.* (1963), is the method of choice for physiological as well as for pharmacological and clinical studies in man.

Radioactive isotopes of inert gases, e.g. ^{133}Xe , ^{135}Xe , ^{85}Kr , $^{85\text{m}}\text{Kr}$, are used as tracers. The basic assumption of these techniques is that there are no barriers limiting the diffusion of the gas between the tissue and the blood. This implies that the equilibrium of gas between the tissue and the blood perfusing it is continuous and instantaneous (Kety, 1951). In this situation, the "mean transit time" of the tracer in the region explored and the "clearance" or "washout rate", in the case of homogeneously perfused tissues, depend only on the blood flow and on the solubility ratio of the gas in tissue and blood; this value is known as the partition coefficient λ . Since the partition coefficient is a constant, the mean transit time and the clearance rate are linear functions of the blood flow through that tissue (Fieschi, 1965; Lassen and Høedt-Rasmussen, 1967).

Changes in concentration of the gamma-emitting radioactive tracer in the brain tissue of man can be recorded from the surface of the head (Fig. 2). Two to three ml. of saline equilibrated with the radioactive gas (approximately 1 mc/ml.) are injected in less than 3 sec into the internal carotid artery, this ensuring that the isotope is distributed to the brain only. For the 10 to 15 min following the injection, curves of radioactivity are recorded by several external detectors. The clearance curve of a diffusible indicator, in the absence of recirculation, can be analysed into two exponential components, showing the average blood-flow values and, in addition, an estimate of the mean flow of the fast and of the slow components and their relative weights (Fig. 2). These four values indicate the flow and the weight of the gray and white matter of the brain. Høedt-Rasmussen *et al.* (1967) and Hutten and Brock (1969) have suggested a non-compartmental analytical approach, based on a stochastic model, to obtain the average rCBF from the mean transit time of the diffusible indicator. Such analyses, however, are completely reliable only if radioactivity is measured with equal efficiency from all parts of the region explored. Measurements *in vivo* deviate from the ideal situation for a number of reasons. These




FIG. 2. *Top*: registration of the clearance curve of ^{85}Kr injected into the internal carotid artery. *Bottom left*: actual record of the clearance curve. Regional blood flow can be calculated from the mean transit time (\bar{t} = area/height of the curve) on the basis of the equation:

$$\frac{1}{\bar{t}} = \frac{F}{V_{\text{Kr}}^{85}} = \frac{F}{\bar{\lambda} W} \times 100$$

where F = rCBF (ml/100 g/min); V_{Kr}^{85} = volume of distribution of ^{85}Kr ; $\bar{\lambda}$ = mean partition coefficient of ^{85}Kr (1.09); W = unit weight of the brain (1 g).

Bottom right: semilogarithmic plot of the clearance curve. Two exponential

Continued overleaf

limiting factors vary according to experimental conditions, such as the collimation and detection systems and the isotope used. For example, resolution and efficiency are poorer with the weak energy of ^{133}Xe than with the stronger energy of the gamma emission of ^{85}Kr , and are even better with ^{135}Xe .

When these methods are used in clinical studies on individual patients, it is important to know the size of the experimental error. Data obtained with ^{85}Kr as a tracer, using five large detectors with crystals of 1.5 in. recessed 3 cm, pulse height analyser and digital ratemeters (Fieschi *et al.*, 1968) showed that, in normal subjects in the resting state, the mean rCBF was 45 ml./100 g/min, and the standard deviation of two subsequent measurements from the same region was 7.5 per cent. Therefore, only differences between two consecutive measurements exceeding twice the limits of this deviation (6.9 ml./100 g/min) are significant; for inter-regional measurements, only differences greater than 34 per cent are significant. In other laboratories the errors may be different depending on the experimental conditions; they are bound to increase when using sixteen or thirty-five probes of smaller size (Fig. 3).

Certain technological advances have been recently suggested: (i) using a shorter recording time, and limiting evaluation of the curve to the initial 2 min (the initial slope method; Hutten and Brock, 1969) and, (ii) an entirely automatic system of data processing using a direct spatial presentation of the regional blood-flow values (Fig. 3) (Sveinsdottir *et al.*, 1969; Fig. 3).

components are evident, showing the blood flow rates of the fast (f_1) and the slow (f_2) compartments and their relative weights (w_1 and w_2). Compartmental analysis is based on the following equations:

$$C(t) = I_1 e^{-k_1 t} + I_2 e^{-k_2 t}$$

where C = recorded radioactivity; I_1 and I_2 = intercepts with the y -axis of the fast and the slow components; k_1 and k_2 = slopes of the fast and the slow components.

$$\text{rCBF} = \frac{I_1 \lambda_1 k_1 + I_2^* \lambda_2 k_2}{I_1 + I_2^*} \times 100 \quad (\text{ml/100 g/min})$$

where λ_1 (= 0.95) and λ_2 (= 1.30) = partition coefficients of ^{85}Kr for the fast and the slow components; I_2^* = intercept of the slow component corrected for the short injection time and partition coefficient

$$\left(I_2^* = I_2 \frac{\lambda_1 k_1}{\lambda_2 k_2} \right)$$

$$w_1 = \frac{I_1}{I_1 + I_2^*} \times 100 \quad ; \quad w_2 = \frac{I_2}{I_1 + I_2^*} \times 100 \quad (\%)$$

$$f_1 = k_1 \lambda_1 \times 100 \quad ; \quad f_2 = k_2 \lambda_2 \times 100 \quad (\text{ml/100 g/min})$$

Kety (1956) has plotted the cerebral blood flow and CMR for O_2 measured by different authors in normal subjects from 5 to 93 years of age (Fig. 4). According to Kety's data the cerebral blood flow and the CMR for O_2 are very high during the first 10 years of life, and decrease somewhat abruptly in adolescence (see p. 205). Thereafter the blood flow and the CMR for O_2 both




FIG. 4. Changes of CBF with aging in normal subjects. From Kety (1956).

decrease progressively. These data are in agreement with the progressive reduction with age of the O_2 tension of the cerebrospinal fluid of the cisterna magna, which is equilibrated with the O_2 capillary tension of the brain (Jarnum *et al.*, 1964).

Subsequent studies have shown that the CBF and CMR for O_2 were the same in young adults and healthy elderly subjects of average age 71. All these subjects were entirely free from physical and mental disease and scored above average for age tests of cognitive function (Dastur *et al.*, 1963). Such data cast some doubt upon the assumption that the decrease of blood flow and metabolism during old age is a truly physiological phenomenon.